Table 2 Main features of included studies (clinical trials)
Author, year | Study design | Treatment strategies | Detailed scheme | Patient characteristics | Main outcome measures | Adverse events | Study duration |
|---|---|---|---|---|---|---|---|
Packham et al., 2016 | Multicenter, randomized, double-blind, dose-escalating, sequential, placebo-controlled trial | Vehicle vs MPC | Two rexlemestrocel-L (allogeneic mesenchymal precursor cells) doses (150 × 106 or 300 × 106) or saline placebo were suspended in 100 mL normal saline and infused with filtration over 45 min. | The study population was male and female patients ≥ 45 and ≤ 85 years old with type 2 diabetes and advanced diabetic nephropathy (e.g., eGFR20—50 mL/min/1.73 m2) who were receiving a stable, standard of care therapeutic regimen of the maximum tolerated recommended dose of an angiotensin converting enzyme inhibitor (ACEI) or a angiotensin 2 receptor blocker (ARB) for at least 3 months prior to screening. | Adverse events; serum creatinine; creatinine clearance; albumin-creatinine ratio; protein-creatinine ratio; cystatin-C; HbA1c; triglycerides; systolic blood pressure; diastolic blood pressure; hs-CRP; IL-6; TNF-α | Edema peripheral; lower respiratory tract infection; urinary tract infection; cataract; anemia; fall; acute myocardial infarction; anemia; asthma; cardiac failure congestive; cardiac failure congestive; syncope; upper gastrointestinal hemorrhage; gangrene; infected skin ulcer; atrial fibrillation; renal failure chronic; benign prostatic hyperplasia; diabetic ulcer; diverticulitis | 60 weeks |